Akeso

Works in Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Oncology · Renal & urogenital · Respiratory · Women's health

Akeso is a clinical trial sponsor. It has 83 active clinical trials with 21,634 planned participants, across 12 therapeutic areas. Since 2021 it has completed 60 trials and stopped 8 early.

Trial track record · since 2021

83Active trials21,634 planned participants
60Completed0 with results posted
8Stopped early12% of finished trials

Pipeline · 83 active trials

StageTrialStatus

On the market · 1 product

  • PENPULIMAB-KCQX penpulimab-kcqx · BLA 761258 · prescription

Questions about Akeso

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-26.

Products come from FDA's drug application database and, for vaccines, cell and gene therapies and blood products, FDA's Purple Book of licensed biologics; checked 2026-09-25.

Approve Suite is not affiliated with Akeso.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.